# A Study of DAT-2645 in Patients With BRCA1/2 Mutations or HRD-Positive Ovarian Cancer

> **NCT07652073** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Danatlas Pharmaceuticals Co., Ltd** · enrollment: 30 (estimated)

## Conditions studied

- Advanced or Metastatic Ovarian Cancer

## Interventions

- **DRUG:** DAT-2645 tablet

## Key facts

- **NCT ID:** NCT07652073
- **Lead sponsor:** Danatlas Pharmaceuticals Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-06-15
- **Primary completion:** 2027-11-30
- **Final completion:** 2028-03-30
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2026-06-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07652073

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07652073, "A Study of DAT-2645 in Patients With BRCA1/2 Mutations or HRD-Positive Ovarian Cancer". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07652073. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*